Momotaro doses first patient with MTG201 in its Phase 2 clinical trial
Category: #healthcare  By Akshay Kedari  Date: 2019-09-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Momotaro doses first patient with MTG201 in its Phase 2 clinical trial
  • The Phase 2 study will register approx. twelve patients diagnosed with malignant mesothelioma that have failed systemic platin-based front-line chemotherapy.
     
  • The key objective of the trial is to evaluate efficacy of MTG201- Nivolumab treatment combination with objective response rate being the primary endpoint.

Momotaro-Gene, a Okayama, Japan based clinical-stage biotherapeutics firm developing new gene therapies for cancer treatment, reportedly announced that it has dosed the first patient in Phase 2 clinical trial that combines MTG201, the lead therapeutic candidate of company, with nivolumab (Opdivo®), PD-1 inhibitor, in patients with malignant pleural mesothelioma that has relapsed. 

The treatment combination of the company’s MTG201 with PD-1 inhibitor has showcased a strong synergistic anti-tumor effect on malignant mesothelioma’s preclinical model.

The Phase 2 clinical trial would be enrolling approx. twelve patients diagnosed with malignant mesothelioma that have failed systemic platin-based front-line chemotherapy. The key objective of the trial is to evaluate efficacy of MTG201- Nivolumab treatment combination with objective response rate (ORR) being the initial endpoint.

Chief Executive Officer of Momotaro-Gene Inc., Hitoshi Shiomi stated that the Phase 2 clinical trial’s initiation demonstrates a vital milestone in the presently active MTG201 development program as it would enable the company to further build upon the positive results that were achieved in the company’s two Phase 1 clinical trials that assessed the treatment. 

Hitoshi also stated that this trial would provide the company with the first human data emphasizing the overall therapeutic potential of integrating MTG201 with a single checkpoint inhibitor, an therapeutic combination the company believes has significant potential based upon preclinical studies.

Hitoshi further added that the company looks forward to work with its collaborators at Baylor College of Medicine for this study and to continue MTG201 advancement as potential treatment option for individuals suffering from an array of cancers.

The Phase 2 clinical trial, being conducted in the Houston, Texas based Baylor College of Medicine, comes after two Phase 1 MTG201 clinical trials showcased encouraging tolerability and safety in patients.

 

Source credit: https://markets.businessinsider.com/news/stocks/momotaro-gene-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mtg201-in-combination-with-nivolumab-in-patients-with-relapsed-malignant-pleural-mesothelioma-1028515931

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

CoreMap Announces Completion of $10.5 Million Series A Financing
CoreMap Announces Completion of $10.5 Million Series A Financing
By Akshay Kedari

CoreMap announced that it has accomplished $10.5 million Series A financing which was led by Qure Ve...

Spain to conduct first trial of Johnson & Johnson’s COVID-19 vaccine
Spain to conduct first trial of Johnson & Johnson’s COVID-19 vaccine
By Akshay Kedari

According to reliable sources, Spain is planning to host the phase 2 clinical trials of the US-based...

Fulcrum Biometrics acquires DelaneyBiometrics, adds European footprint
Fulcrum Biometrics acquires DelaneyBiometrics, adds European footprint
By Akshay Kedari

Fulcrum Biometrics, Inc. has announced a strategic acquisition of Delaney Secure Ltd., a UK-based bi...